The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://haimaevlh946171.wikijournalist.com/5823118/retatrutide_vs_tirzepatide_a_comparative_analysis